STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro

Haixiao Wang1,4,#, Kuangjie Wu1,#, Yuan Sun5, Yandong Li2,3, Mingyu Wu1, Qian Qiao1, Yuanjiang Wei1, Ze-Guang Han2,3,* & Bing Cai1,*

1Department of Hepatobiliary Surgery, Wuxi People’s Hospital of Nanjing Medical University, Jiangsu, 2Chinese National Human Genome Center, Rui-Jin Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, 3Shanghai-MOST Key Laboratory for Disease and Health Genomics, Chinese National Human Genome Center at Shanghai, 4Department of General Surgery, Huaian No. 1 People’s Hospital Affiliated to Nanjing Medical University, Huaian, Jiangsu Province, 5Department of Pharmacy, Huaian No. 1 People’s Hospital Affiliated to Nanjing Medical University, Huaian, Jiangsu Province, China

The human glycoprotein, stanniocalcin 2 (STC2) plays multiple roles in several tumor types, however, its function and clinical significance in hepatocellular carcinoma (HCC) remain unclear. In this study, we detected STC2 expression by quantitative real-time PCR and found STC2 was upregulated in HCC tissues, correlated with tumor size and multiplicity of HCC. Ectopic expression of STC2 markedly promoted HCC cell proliferation and colony formation, while silencing of endogenous STC2 resulted in a reduced cell growth by cell cycle delay in G0/G1 phase. Western blot analysis demonstrated that STC2 could regulate the expression of cyclin D1 and activate extracellular signal-regulated kinase 1/2 (ERK1/2) in a dominant-positive manner. Transwell chamber assay also indicated altered patterns of STC2 expression had an important effect on cell migration. Our findings suggest that STC2 functions as a potential oncoprotein in the development and progression of HCC as well as a promising molecular target for HCC therapy. [BMB Reports 2012; 45(11): 629-634]

INTRODUCTION

Hepatocellular carcinoma (HCC) is a highly virulent malignancy and its incidence has increased rapidly during the past few decades worldwide, with only 9% of patients surviving more than 5 years (1, 2). About half of the cases and deaths are estimated to occur in China. Hepatitis B or C viral infection, alcohol abuse and aflatoxin intake are the most common etiologies for the development of HCC. In recent years, advances in therapeutic modalities and strategies have improved the chance of curative treatment for HCC. Liver transplantation and surgical resection are regarded as the main therapeutic treatment after considering tumor extent and hepatic functional reserve (3). And molecular targeted chemotherapy such as sorafenib and monoclonal antibodies can also significantly improve the long-term survival of HCC patients (4). Because the genetic heterogeneity of different patients affect their response to chemotherapy and the limits of other therapies exist, the HCC patients’ long-term prognosis is still poor for the metastasis and the frequent recurrence (4, 5).

During HCC tumorigenesis and progression, specific alterations in oncogenes and tumor suppressor-genes are required (6, 7). Hence identifying novel oncogenes as HCC therapeutic agents is a focal point of anti-cancer research. Stanniocalcin (STC) is a family of secreted glycoprotein hormones that originally discovered in the corpuscles of Stannius, an endocrine gland of fish (8, 9). STC1 and STC2, two homologues of STC family, are reported to involve in calcium and phosphate homeostasis (10, 11). Both two proteins differ at C-terminal half but share similar hydropathy profiles at the N-terminal half (12). STC1 is the first discovered Stanniocalcin family member and has been implicated to participate in different physiological functions (13, 14). STC2 is widely expressed in human tissues with high transcripts levels in skeletal muscle, heart and pancreas (12, 15). Several reports have revealed that STC2 overexpression could promote tumor cell proliferation, invasion and metastasis in prostate cancer, ovarian cancer or neuroblastoma (16-18).

STC2 is also vital for cytoprotective properties when exposed to ER stress and hypoxia (19, 20). Although STC2 is well-known in other tumor types, the relationship between STC2 and HCC has not yet been reported so far.

In this current study, we examined the expression pattern of STC2 in HCC specimens and cell lines, and analyzed the potential correlation between STC2 and HCC. In addition, we also tested its effect on cell proliferation and migration, and investigated the potential role of STC2 on HCC cell cycle transition.
STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro
Haixiao Wang, et al.

RESULTS

STC2 is frequently upregulated in HCC
To evaluate the expression pattern of STC2 in HCC tissues, we performed quantitative real-time PCR approach in 44 pairs of HCCs and non-HCCs. The results indicated that STC2 was significantly upregulated in HCCs compared with the paired non-HCC tissues (Fig. 1A, \( P < 0.0001 \)). Among the 44 pairs of clinical samples, 35/44 (79.5%) showed STC2 upregulation (T/N ≥ 1.5), 21/44 (47.7%) (T/N ≥ 5) had severe STC2 increase. 7/44 (15.9%) had no difference (1.5 > T/N ≥ 1), and 2/44 (4.5%) was downregulated (1 > T/N ≥ 0.5) (Fig. 1B). Moreover, total proteins were extracted from random 8 paired HCCs and paratumor tissues. The protein expression of STC2 was determined by western blot using a polyclonal antibody to STC2. 7/8 (87.5%) were significantly elevated in HCCs than paired non-HCC tissues in line with the quantitative real-time PCR results (Fig. 1C).

Subsequently, we accessed the correlation between STC2 expression and clinicopathological characteristics in HCC. The results demonstrated STC2 mRNA levels were higher in samples with diameter of tumor ≥ 5 cm than those < 5 cm, and in samples with multiple tumors than those with a single tumor (Supplemental Table 1, \( P < 0.05 \)). Furthermore, it was trend to be associated with the high TNM staging (II/III/IV) of HCC (Supplemental Table 1, \( P=0.063 \)). Other clinicopathologic parameters, such as sex, patient age (≤ 50 years vs > 50 years), HBsAg, liver cirrhosis, Child-Pugh score, serum AFP, tumor differentiation, tumor encapsulation and microvascular invasion are not significantly related to the upregulation of STC2 (Supplemental Table 1, \( P > 0.05 \)). In addition, we measured the protein expression level of STC2 in available 8 HCC cell lines by western blot analysis. The results showed that STC2 level was higher in MHCC-97H, MHCC-97L and MHCC-LM6 cells, which all possess high metastatic potential (Fig. 1D). Taken together, the expression pattern of STC2 in clinical samples and cell lines suggested it may play an important role in the pathogenesis of HCC.

Finally, we explored the underlying mechanism of STC2 functions in HCC. Therefore, the data strongly indicated that STC2 might represent as a promising novel therapeutic target for HCC.
STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro

Haixiao Wang, et al.

STC2 overexpression promotes cell proliferation and colony formation

Since a high STC2 mRNA expression is associated with larger tumor size (Supplemental Table 1), we first evaluated the effect of STC2 overexpression on HCC cell growth. Compared to the empty vector control, STC2 overexpression markedly promoted cell proliferation of YY-8103 cells (Fig. 2B, P < 0.01). To further confirm the cell growth promotion induced by STC2, we performed colony formation assays and the result illustrated that ectopic expression of STC2 dramatically increased the number of colonies relative to controls (Fig. 2C, P < 0.05). These data indicated that STC2 is essential to maintain HCC cell proliferation.

Silencing of endogenous STC2 suppresses cell growth and colony formation of HCC cells

To investigate the effect of STC2 depletion on cellular growth and colony formation of HCC cells, cell proliferation and colony formation assays were employed. As shown in Fig. 3A and C, the siRNA-mediated or pSUPER-shRNA-mediated RNA interference dramatically reduced the STC2 mRNA expression level of MHCC-97H cells compared with the control si-NC or pSUPER-shNC. STC2 knockdown could significantly suppress cell growth and colony formation of MHCC-97H relative to the controls (Fig. 3B and D, P < 0.05). The same impacts of STC2 silencing on cell proliferation and colony formation were also observed in MHCC-97L cells (Fig. 3).

To elucidate the mechanism by which STC2 affects cell growth, we investigated the cell cycle profile of MHCC-97H and MHCC-L cells by flow cytometry. As shown in Fig. 3E, the populations of cells in G0/G1 phase increased remarkably while this G0/G1 arrest correlated with a decrease in the S phase population in both cell lines at 72 hours after STC2 knockdown by si-STC2 (Fig. 3E, P < 0.05). This result suggested that STC2 affects cell growth through involving in G1 to S transition of cell cycle progression.

STC2 positively regulates cyclin D1 and pERK1/2 expression

Cyclin D1 is required for cell cycle progression from G1 to S phase (21). To explore the mechanism by which STC2 induces G0/G1 phase arrest, the expression level of cyclin D1 was monitored by western blot. The results showed that the protein level of cyclin D1 was significantly reduced in MHCC-97H and MHCC-97L cells when treated with si-STC2 (Fig. 4). In contrast, STC2 overexpression increased the protein level of cyclin D1 in YY-8103 cells. As known, sustained ERK1/2 activity is required for the continued expression of cyclin D1 in G1 phase. We next assessed the phosphorylation level of ERK1/2 and western blot results demonstrated that phosphorylated ERK1/2 was increased in YY-8103 cells transfected with STC2 plasmid and decreased in MHCC-97H and MHCC-97L cells when treated with si-STC2 (Fig. 4). Cyclin D1 ex...
of proliferation between the treated cells and controls within 72 hours. The proliferation assay was employed. Etopic expression of STC2 showed no significant impacts on PLC/PRF/5 and Sk-hep-1 cellular proliferation ability compared to the control cells (Fig. S1A and B, P < 0.0001). And STC2 siRNA silencing blocked cell proliferation in experimental HCC cell lines dramatically suppressed cell proliferation (Fig. S2A). Meantime STC2 knockdown did not affect cell growth in MHCC-LM6 cells within 72 hours (Fig. S2B). Taken together, these data suggested that STC2 can dramatically enhance HCC cell proliferation independent of cell proliferation.

**DISCUSSION**

To the best of our knowledge, the present study is the first report to validate mRNA and protein levels of STC2 in HCC and highlights the oncogenic role of STC2 in HCC. Among the 44 pairs of HCC tissues detected in this study by quantitative real-time PCR, STC2 was frequently upregulated in HCC tumor tissues relative to matched nontumorous samples. Furthermore, we also showed that STC2 protein level was increased in 8 representative pairs of HCC samples. Thus, the expression pattern of STC2 in HCC is consistent with that in other tumors, implying that STC2 may play a similar role in various different tumor types. The analysis of clinical correlation illustrated that STC2 overexpression in HCC was associated with tumor size and tumor multiplicity, meanwhile, HCC cell lines with high STC2 expression are abundant with migration property. These data indicated that STC2 might boost HCC carcinogenesis and metastasis. As expected, cell biology experiments performed in this study revealed that STC2 overexpression promoted HCC cell proliferation and migration, and STC2 knockdown led to a suppression of cell growth and migration in vitro. Therefore, in this report, we have added new information about STC2 in tumor development.

Recent evidences suggested that STC2 is a poor prognostic marker for patients with renal cell carcinoma, gastric cancer and et al. (22, 23), while it is correlated with longer disease-free survival in breast cancer (24). Intriguingly, Schmitz KJ reported that activation of ERK1/2 in HCC was strongly correlated with a reduced overall survival and served as a significant predictor of prognosis (25). Importantly, large tumor size is a detrimental prognostic factor and tumor multiplicity is also an independent risk factor for survival and tumor recurrence in HCC (26). As a secreted protein, STC2 may be identified as a potential promising biomarker to monitor the recurrence and prognostic after treatment of HCC, which is required for further investigation.

As reported by many studies, the regulation of cell cycle G1/S check-point was usually abnormal in tumor cells. To address the biological function of STC2 in HCC cells, flow cytometric analysis of MHCC-97H and MHCC-97L cells revealed that knockdown of STC2 arrested the cells in G0/G1 or at the G1/S border. Concomitant with cell cycle arrest, STC2 knockdown decreased the phosphorylated ERK1/2 level and induced a reduction of cyclin D1. Since both ERK1/2 and cyclin D1 are responsible for G1/S transition, our data indicated at molecular level that STC2 knockdown blocked cell cycle progression in experimental HCC cells. In support of this conclusion, when STC2 was overexpressed in YY-8103 cells, we also observed an increase in phosphorylated ERK1/2 and cyclin D1 level by western blot.

In summary, we present data that STC2 affects HCC cells viability, colony formation and migration ability in a dominant-positive manner. Furthermore, STC2 regulates cell cycle transition from G1 to S phase. Finally, the protein level of cyclin D1 and pERK1/2 was decreased in STC2-dowreglated cells (MHCC-H and MHCC-L) and increased in STC2-upregulated cells (YY-8103). All the data suggest that the upregulation of STC2 contributes to HCC progression and metastasis. The results of the present study not only help to understand the role of STC2 in HCC tumorigenesis and progression, but also strongly imply that STC2 might represent as a novel biomarker and a promising therapeutic target for the intervention of HCC in the Stanniocalcin family.
MATERIALS AND METHODS

Tissue specimens and cell culture
In this study, paired HCCs and adjacent paratumor liver tissues from 44 patients incorporating HCCs were obtained with informed consent. The experiments were approved by the Ethics Committee of the Wuxi People’s Hospital. Clinical and pathological information was extracted from medical charts and pathology reports of these patients. The clinicopathological characteristics of the patients and their cancers are detailed in Supplemental Table 1. HCC cell lines were from American Type Culture Collection (Manassas). Cells were grown in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum and antibiotics (50 U/ml penicillin and 50 μg/ml streptomycin) (Gibco) at 37°C in 5% CO₂.

RNA extraction and quantitative real-time PCR
Total RNA was extracted by TRIzol reagent (Invitrogen) and reverse-transcribed into cDNA using M-MLV reverse transcriptase kit (Promega). The following primers were used to specifically amplify the STC2 gene and β-actin (monitored as a control). The primer sequences were: STC2, forward primer, 5’-ATGCTACCTC AAGCAGACC-3’; reverse primer, 5’-TCTGGTCACACTGAACC TGC-3’. β-actin, forward primer, 5’-AGAGCTTCGCTTGGCC GATCC-3’; reverse primer, 5’-CTGGGCTCTTGCTGCCCACATA 3’ The copy number of each sample was calculated and all the data were normalized to β-actin prior to comparative analysis using 2⁻^ACT method (27).

Plasmid construction
The open reading frame (ORF) of STC2 (human, NM 003714) was amplified by PCR from the cDNA of MHCC-97H cells. STC2 ORF was inserted into the c-myc-tagged pcDNA3.1(B) expression vector (Invitrogen) to construct pcDNA3.1-STC2 plasmid according to the manufacturer’s protocol.

Cell transfection
Cell transfection was conducted using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.

RNA interference
For siRNAs transfection, STC2-specific small interference RNA (siRNA) and the non-specific control siRNA were chemically synthesized by GenePharma. The special siRNA sequences used were as follows: siRNA-STC2 (sense 5’-GUUGGAAGUAUCC UUUCAATT-3’ and antisense 5’-UGAAUGUCAUCUCCAC TT -3’). The non-specific siRNA not targeting any annotated human genes was used as negative control. Moreover, for the construction of the RNAi plasmid, the special oligonucleotide fragment encoding short hairpin RNA (shRNA) for STC2 silencing was cloned into the pSUPER vector (OligoEngine). The oligonucleotide sequences for shRNA were: shRNA_STC2, forward, GAT CCCCCGTGAGATGATCCTTTCCATCCAGAGATGAAATTGGA TCATCTCCACTTTTGGAA; reverse, AGCTTTTCTAAAAAGTG GAGATGATCCTTGGTAATGAAATTGGA TCATCTCCACTTTTGGAA.

Cell proliferation and colony formation assay
HCC cells were seeded into 96-well plates at a density of 3×10³ cells per well in 100 μl medium. The absorbance values were determined at a wavelength of 450 nm using Cell Counting Kit-8 (Dojindo Laboratories) according to the manufacturer’s manual. Cells transfected with vector or pcDNA3.1-STC2 were plated at a density of 8×10⁴ per 10 cm plate and selected in appropriate medium of 0.8 mg/ml G418 (Life Technologies) for colony formation at 37°C in 5% CO₂. After three weeks, the cells were rinsed with PBS, fixed with paraformaldehyde and stained with coomassie brilliant blue. The colonies were photographed and statistically analyzed.

Cell cycle analysis
The treated cells were harvested as single cell suspensions, washed with PBS and incubated with propidium iodide (10 μg/ml) and RNase A (10 mg/ml) for 30 min at 4°C in the dark. Cell cycle distribution was analyzed by a FACS Calibur flow cytometer (Becton-Dickinson).

Western blot analysis
The treated cells were washed twice with cold PBS and scraped off from the plates. Cells were resuspended in cold lysis buffer [25 mMol/L Tris (pH 6.8), 1% SDS, 5 mMol/L EDTA, protease inhibitor cocktail (Sigma)]. Tissue specimens were ground in Liquid nitrogen and lysed in RIPA lysis buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.1% SDS]. The blotted membrane was incubated overnight with the primary antibody at 4°C. The membrane was incubated with the secondary antibody for 1h at room temperature. Mouse antibody to cyclin D1 (Santa Cruz Biotechnology), and rabbit antibodies to STC2 (Abcam), pERK1/2 and total ERK1/2 (cell signaling technology) were used in this study.

Cell migration assay
The migration ability of HCC cells was assessed using the Transwell chambers. 3×10³ cells were resuspended in 300 μl DMEM without FBS. Then cells were plated in the upper chamber of 24-well transwells without matrigel and 750 μl DMEM containing 10% FBS were added to the lower chamber. After incubated for 36 h at 37°C in 5% CO₂, cells located upon the upper membranes were wiped with cotton swabs. The cells migrated to the lower surface of membrane were fixed in ethanol and stained with crystal violet. The migrated cells in five random fields (magnification, ×100) were photographed and counted for each group. The migration capability of cell was determined by the average number of migrated cells in the five fields.

Statistical analysis
All experiments were repeated at least three times and each ex-
periment was performed at least in duplicate. All results are presented as mean ± standard deviations. Statistical analysis was performed using Student’s t test analysis from GraphPad Prism-5.0. P value < 0.05 was considered statistically significant.

Acknowledgements

This work was supported by grants from the Academician Workstation of Wuxi People’s Hospital (CYE00917), and the Chinese National Key Program on Basic Research (2010CB-529204), and the China National Key Projects for Infectious Disease (2008ZX10002-021).

REFERENCES

1. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. CA Cancer J. Clin. 61, 69-90.

2. Sherman, M. (2005) Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 25, 143-154.

3. Hwang, S., Moon, D. B. and Lee, S. G. (2010) Liver transplantation and conventional surgery for advanced hepatocellular carcinoma. Transpl. Int. 23, 723-727.

4. Villanueva, A. and Llovet, J. M. (2011) Targeted therapies for hepatocellular carcinoma. Gastroenterology. 140, 1410-1426.

5. Livraghi, T., Makisalo, H. and Line, P. D. (2011) Treatment options in hepatocellular carcinoma today. Scand. J. Surg. 100, 22-29.

6. Zender, L., Spector, M. S., Xue, W., Flemming, P., Cordon-Cardo, C., Sille, J., Fan, S. T., Luk, J. M., Wigler, M., Hannon, G. J., Mu, D., Lucito, R., Powers, S. and Lowe, S. W. (2006) Identification and validation of oncogenes in liver cancer using an integrative oncogenic approach. Cell 125, 1253-1267.

7. Levine, A. J. and Puzio-Kuter, A. M. (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 330, 1340-1344.

8. Flik, G., Labedz, T., Neelissen, J. A., Hansen, R. G., Wendelaar Bonga, S. E. and Pang, P. K. (1990) Rainbow trout stanniocalcin synthesis in vivo. Am. J. Physiol. 258, R1157-1164.

9. Sterba, T., Wagner, G. F., Schroeder, J. C. and Friessen, H. G. (1993) In situ detection and distribution of stanniocalcin mRNA in the corpuscles of Stannius of sockeye salmon, Oncorhynchus nerka. Mol. Cell Endocrinol. 90, 179-185.

10. Honda, S., Kashiwagi, M., Ookata, K., Tojo, A. and Hirose, S. (1999) Regulation by TGFalpha, 25-dihydroxyvitamin D3(3) of expression of stanniocalcin messages in the rat kidney and ovary. FEBS Lett. 459, 119-122.

11. Wagner, G. F., Jaworski, E. M. and Haddad, M. (1998) Stanniocalcin in the seawater salmon: structure, function, and regulation. Am. J. Physiol. 274, R1177-1185.

12. Ishihashi, K., Miyamoto, K., Taketani, Y., Morita, K., Takeda, E., Sasaki, S. and Imai, M. (1998) Molecular cloning of a second human stanniocalcin homologue (STC2). Biochem. Biophys. Res. Commun. 250, 252-258.

13. Nguyen, A., Chang, A. C. and Reddel, R. R. (2009) Stanniocalcin-1 acts in a negative feedback loop in the prosurvival ERK1/2 signaling pathway during oxidative stress. Oncogene. 28, 1982-1992.

14. Lai, K. P., Law, A. Y., Yeung, H. Y., Lee, L. S., Wagner, G. F. and Wong, C. K. (2007) Induction of stanniocalcin-1 expression in apoptotic human nasopharyngeal cancer cells by p53. Biochem. Biophys. Res. Commun. 356, 968-975.

15. Moore, E. E., Kuestner, R. E., Conklin, D. C., Whitmore, T. E., Downey, W., Buddle, M. M., Adams, R. L., Bell, L. A., Thompson, D. L., Wolf, A., Chen, L., Stamm, M. R., Grant, F. J., Lok, S., Ren, H. and De Jongh, K. S. (1999) Stanniocalcin 2: characterization of the protein and its localization to human pancreatic alpha cells. Horm. Metab Res. 31, 406-414.

16. Tamura, H., Furuhata, M., Chung, S. Y., Uemura, M., Yoshioka, H., Iyama, T., Ashida, S., Nasu, Y., Fujioka, T., Shuin, T., Nakamura, Y. and Nakagawa, H. (2009) Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer. Cancer Sci. 100, 914-919.

17. Law, A. Y. and Wong, C. K. (2010) Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp. Cell Res. 316, 3425-3434.

18. Volland, S., Kugler, W., Schweigerer, L., Wilting, J. and Becker, J. (2009) Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma. Int. J. Cancer. 125, 2049-2057.

19. Fazio, E. N., Dimattia, G. E., Chadi, S. A., Kernohan, K. D., Pin CL. (2011) Stanniocalcin 2 alters PERK signalling and reduces cellular injury during cerulein induced pancreatitis in mice. BMC Cell Biol. 12, 17.

20. Ito D, Walker, J. R., Thompson, C. S., Moroz, I., Lin, W., Veselits, M. L., Hakim, A. M., Fienberg, A. A., Thinakaran, G. (2004) Characterization of stanniocalcin 2, a novel target of the mammalian unfolded protein response with cytoprotective properties. Mol. Cell Biol. 24, 9456-9469.

21. Tarn, W. Y. and Lai, M. C. (2011) Translational control of cyclins. Cell Div. 6, 5.

22. Meyer, H. A., Tölle, A., Jung, M., Fritzsche, F. R., Haendler, B., Kristiansen, G. (2009) Identification of stanniocalcin 2 as a prognostic marker in renal cell carcinoma. Eur Urol. 55, 669-678.

23. Yokobori, T., Mimori, K., Ishii, H., Iwatsuki, M., Tanaka, F., Kamohara, Y., Ieta, K., Yita, D., Doki, Y., Kuwano, H. and Mori, M. (2010) Clinical significance of stanniocalcin 2 as a prognostic marker in gastric cancer. Ann. Surg. Oncol. 17, 2601-2607.

24. Yamamura, J., Miyoshi, Y., Tanaka, Y., Taguchi, T., Iwao, K., Monden, M., Kato, K. and Noguchi, S. (2004) mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers. Cancer Sci. 95, 887-892.

25. Schmitz, K. J., Wohlschlager, J., Lang, H., Sotropoulos, G. C., Malago, M., Steveling, K., Reis, H., Cicinnati, V. R., Schmid, K. W. and Baba, H. A. (2008) Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J. Hepatol. 48, 83-90.

26. Qin, L. X. and Tang, Z. Y. (2002) The prognostic significance of GFRalpha-2 expression in gastric cancer. Scand. J. Gastroenterol. 37, 669-678.

27. Too, H. P. (2003) Real time PCR quantification of GFRalpha-2 alternatively spliced isoforms in murine brain and peripheral tissues. Brain Res. Mol. Brain Res. 114, 146-153.